• Patent Agent Registration: Canada, U.S. (2004,2005)
  • Ph.D., Biochemistry, Stanford University (1993)
  • B.S., Molecular Biophysics and Biochemistry, Yale University (1986) (summa cum laude, Phi Beta Kappa, with Distinction in the Major)


French version is available here.

Emma is an experienced patent agent specializing in intellectual property since 2000. She practices in all areas of chemistry and the life sciences, with a broad range of experience in Canadian, U.S., and foreign patent prosecution, strategic IP portfolio development and management, patentability and freedom-to-operate analysis, opinions, due diligence evaluations, and litigation support.

Emma has particular expertise in pharmaceuticals, biotechnology, bio-organic chemistry, green chemistry, diagnostics, therapeutics, vaccines, nutraceuticals, functional genomics and proteomics, coatings, and clean technologies. She has represented a comprehensive range of clients from individuals to multinational corporations, including start-ups, early-stage ventures, universities, research organizations, and pharmaceutical companies.

Prior to joining private practice, Emma was Director for Intellectual Property at Neurochem Inc., where she was responsible for managing and maintaining the company's patent and trademark portfolios worldwide.

Professional affiliations

  • Intellectual Property Institute of Canada (IPIC) (Member since 2005); Director, McGill University’s Understanding Patents Course (2011-2013); Lecturer and Tutor, McGill University’s Understanding Patents Course (2007-present); IPIC Patent Agent Training Course Committee (2007-2013); IPIC-CIPO Joint Liaison Committee - Patents (2007-2011); IPIC Technology Transfer Committee (2013-2014)

  • Alliance for Commercialization of Canadian Technologies (ACCT) (Member since 2011); Program Committee for the Annual Meeting (2011,2012)

  • Association of University Technology Managers (AUTM) (Member since 2011)

  • Intellectual Property Owners Association (IPO) (Member since 2006); International Patent Law and Practice Committee (2010 - present)

  • American Intellectual Property Law Association (AIPLA) (Member since 2008)

  • Canadian Institute For Health Research, Proof-of-Principle Grant Peer Review Committee (2009-present)

  • Springboard Atlantic Canada, Proof-of-Principle Grant Review Committee (2009, 2010)

  • Montreal Neurological Institute, CECR Commercialization Committee (2008-2010)


  • “Practical Advice after the U.S. Supreme Court Decision in Myriad,” ACCT Innovation Conference, (2013)

  • “What you need to know about the America Invents Act (AIA) in the U.S.,” Norton Rose CLE Conference, (2013)

  • “From Researcher to Patent Agent: An Introduction to IP,” Survival Skills for Scientists Workshop, École de technologie supérieure, (2013)
  • “CIHR’s Proof-of-Principle Program,” New Investigator Forum, CIHR Institute of Infection and Immunity, (2013)
  • “The Do's and Don'ts of Patenting: An Introduction to IP,” BioEntrepreneur Workshop, University of Ottawa, (2012)
  • “The Role of Patents in the Biotech Industry,” Montreal Biotech Investment Club, 2011
  • “Personalized Medicine: At the Frontiers of Law and Medicine,” Norton Rose Pharmaceuticals CLE conference, (2011)
  • “Publish or Patent? The Role of Patents in Biotechnology,” McGill BioConnect Symposium, 2010
  • “Utility, Sound Prediction and Selection Patents,” 9th Annual Pharma Patents conference, The Canadian Institute, (2010)
  • “Life Sciences in the Era of Bilski,” Norton Rose CLE Conference, Montreal & Ottawa, (2009)
  • “Intellectual Property in Drug Design,” McGill University, (2007)
  • “If You Build It, Will They Come? Growing and Maintaining a Competitive Advantage with IP,” Law, Symposium, Boston, Massachusetts, (2003)


  • Saffman, E.E. and Lasko, P. 1999. Germline development in vertebrates and invertebrates. Cellular and Molecular Life Sciences 55: 1141-1163. (literature review)
  • Saffman, E.E., Styhler, S., Rother, K., Li, W., Richard, S., and Lasko, P. 1998. Premature translation of oskar in oocytes lacking the RNA-binding protein Bicaudal-C. Molecular and Cellular Biology 18: 4855-4862.
  • Mahone, M., Saffman, E.E., and Lasko, P.F. 1995. Localized Bicaudal-C RNA encodes a protein containing a KH domain, the RNA binding motif of FMR1. EMBO Journal 14: 2043-2055.
  • Saffman, E.E. and Krasnow, M.A. 1994. A differential response element for the homeotics at the Antennapedia P1 promoter of Drosophila. Proceedings of the National Academy of Sciences USA 91: 7420 - 7424.
  • Krasnow, M.A., Saffman, E.E., Kornfeld, K., and Hogness, D.S. 1989. Transcriptional activation and repression by Ultrabithorax proteins in cultured Drosophila cells. Cell 57: 1031-1043.


514 397-4756

Download my vCard


Virginia Delgado

514 397-6699 #3470


25th Floor
1100 René-Lévesque Blvd West
Montreal, Quebec   H3B 5C9
tel. : 514 397-8500
fax : 514 397-8515